
NPRRF
Real Estate · REIT - Residential · $1.42B market cap
$8.710.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 10, 2026 | After the close | 13.55 | 0.13 | -99.0% |
| Feb 9, 2026 | After the close | 34.39 | 0.38 | -98.9% |
| Nov 10, 2025 | After the close | 27.76 | 0.10 | -99.7% |
| Aug 8, 2025 | After the close | 29.61 | 0.12 | -99.6% |
| Feb 7, 2025 | Time not confirmed | — | 0.23 | — |
| Feb 8, 2022 | Before the open | — | 22.90 | — |
| Nov 9, 2021 | Before the open | — | 24.54 | — |
| Aug 10, 2021 | Before the open | — | 20.24 | — |
| May 11, 2021 | Before the open | — | 23.50 | — |
| Feb 8, 2021 | Time not confirmed | — | 30.07 | — |
| Nov 9, 2020 | Time not confirmed | 25.80 | 14.98 | -41.9% |
| Aug 7, 2020 | Before the open | 19.00 | 18.58 | -2.2% |
| May 11, 2020 | Before the open | — | -141.88 | — |
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical Device business develops, manufactures, and sells medical equipment for injection-infusion and dialysis treatment, and products related to diabetes and cell cultures, as well as the sale of artificial organ-related products. The company's Pharmaceutical business provides…
| Feb 6, 2020 |
| Before the open |
| — |
| 30.49 |
| — |
| Nov 7, 2019 | Before the open | — | 18.97 | — |
| Aug 8, 2019 | Before the open | — | 17.12 | — |
| Feb 7, 2019 | Time not confirmed | — | 13.76 | — |
| Nov 8, 2018 | Time not confirmed | — | 17.71 | — |
| Aug 9, 2018 | Before the open | — | 28.14 | — |
| May 10, 2018 | Before the open | 22.36 | -12.01 | -153.7% |
| Feb 8, 2018 | Before the open | 38.50 | 33.33 | -13.4% |